Advertisement
Screener

Citius Oncology, Inc. (CTOR) Price / Book

2.8 / 5 stars · 68/120 Roast Me

CITIUS ONCOLOGY, INC. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

  • CITIUS ONCOLOGY, INC. price/book ratio for the quarter ending 2026-06-30 was 1.7, a 82.52% decline year-over-year.
  • CITIUS ONCOLOGY, INC. price/book ratio for the quarter ending 2026-03-31 was 1.63, a 12.49% decline year-over-year.
  • CITIUS ONCOLOGY, INC. price/book ratio for the quarter ending 2025-12-31 was 1.42, a 28.69% decline year-over-year.
  • CITIUS ONCOLOGY, INC. price/book ratio for the quarter ending 2025-09-30 was 3.72, a 72.71% increase year-over-year.
  • CITIUS ONCOLOGY, INC. price/book ratio for fiscal 2026 was 1.7.
  • CITIUS ONCOLOGY, INC. price/book ratio for fiscal 2025 was 1.42, a 28.69% decline from fiscal 2024.
  • CITIUS ONCOLOGY, INC. price/book ratio for fiscal 2024 was 1.99, a 76.84% increase from fiscal 2023.
  • CITIUS ONCOLOGY, INC. price/book ratio for fiscal 2023 was 1.13, a 98.41% decline from fiscal 2022.
Available history
2022-12-31 to 2026-06-30
Data captured

Historical Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-301.7$68.74M$40.38M
2026-03-311.63$57.62M$35.27M
2025-12-311.42$83.02M$58.41M
2025-09-303.72$167.03M$44.87M
2025-06-309.74$315.55M$32.4M
2025-03-311.87$66.54M$35.64M
2024-12-311.99$82.29M$41.29M
2024-09-302.16$99.46M$46.14M
2024-06-301.56$26.59M$17.03M
2024-03-311.3$25.89M$19.85M
2023-12-311.13$25.61M$22.73M
2023-09-3028.47$726.98M$25.54M
2023-06-30-12,927.07$25.44M-$1,968.00
2023-03-31126.49$24.99M$197,586.00
2022-12-3171.04$24.55M$345,508.00

Annual Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-301.7$68.74M$40.38M
2025-12-311.42$83.02M$58.41M
2024-12-311.99$82.29M$41.29M
2023-12-311.13$25.61M$22.73M
2022-12-3171.04$24.55M$345,508.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
Anixa Biosciences Inc (ANIX)United States$0.096B
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
ProMIS Neurosciences Inc. (PMN)$0.102B
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Equillium, Inc. (EQ)United States$0.109B-11.27